TELA Bio, Inc. Common Stock (TELA)
TELA Bio, Inc. is a biotechnology company focused on developing and commercializing novel tissue repair products derived from its proprietary decellularization and sterilization technologies. The company specializes in products designed to facilitate soft tissue repair and reconstruction, primarily in the fields of orthopedics and surgical applications. TELA aims to improve patient outcomes by providing advanced, biocompatible tissue solutions.
Company News
The global hernia repair devices market is projected to reach US$ 6.57 billion by 2033, driven by rising procedural volumes, technological advancements, and increasing adoption of minimally invasive techniques. Key trends include the shift towards mesh implants, competition between open and laparoscopic repair, and the growing use of robotic plat...
TELA Bio, a medical technology company, announced the closing of its public offering of common stock and pre-funded warrants, raising $46 million. The company plans to use the proceeds for general corporate purposes.
Vertex (VRTX) delivered earnings and revenue surprises of 16.10% and 5.15%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
In our monthly Rare Stock Picks series, we're highlighting January 2024 investment picks. Click here for the list of January 2024 Buy recommendations.
TELA earnings call for the period ending June 30, 2022.